Das Riku, Mahabeleshwar Ganapati H, Kundu Gopal C
National Center for Cell Science (NCCS), NCCS Complex, Pune 411 007, India.
J Biol Chem. 2004 Mar 19;279(12):11051-64. doi: 10.1074/jbc.M310256200. Epub 2004 Jan 2.
We have recently reported that osteopontin (OPN) stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase-type plasminogen activator (uPA) through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells (Das, R., Mahabeleshwar, G. H., and Kundu, G. C. (2003) J. Biol. Chem. 278, 28593-28606). However, the role(s) of OPN on AP-1-mediated uPA secretion and cell motility and the involvement of c-Src/epidermal growth factor receptor (EGFR) in these processes in breast cancer cells are not well defined. In this study we report that OPN induces alpha(v)beta(3) integrin-mediated c-Src kinase activity in both highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. Ligation of OPN with alpha(v)beta(3) integrin induces kinase activity and tyrosine phosphorylation of EGFR in MDA-MB-231 and wild type EGFR-transfected MCF-7 cells, and this was inhibited by the dominant negative form of c-Src (dn c-Src) indicating that c-Src kinase plays a crucial role in this process. OPN induces association between alpha(v)beta(3) integrin and EGFR on the cell membrane in a macromolecular form with c-Src. Furthermore, OPN induces alpha(v)beta(3) integrin/EGFR-mediated ERK1/2 phosphorylation and AP-1 activation. Moreover, dn c-Src also suppressed the OPN-induced phosphatidylinositol (PI) 3-kinase activity in these cells indicating that c-Src acts as master switch in regulating MEK/ERK1/2 and phosphatidylinositol 3-kinase/Akt signaling pathways. OPN-induced ERK phosphorylation, AP-1 activation, uPA secretion, and cell motility were suppressed when cells were transfected with dn c-Src or pretreated with alpha(v)beta(3) integrin antibody, c-Src kinase inhibitor (pp2), EGFR tyrosine kinase inhibitor (PD153035), and MEK-1 inhibitor (PD98059). To our knowledge, this is the first report that OPN induces alpha(v)beta(3) integrin-mediated AP-1 activity and uPA secretion by activating c-Src/EGFR/ERK signaling pathways and further demonstrates a functional molecular link between OPN-induced integrin/c-Src-dependent EGFR phosphorylation and ERK/AP-1-mediated uPA secretion, and all of these ultimately control the motility of breast cancer cells.
我们最近报道,骨桥蛋白(OPN)通过磷脂酰肌醇3激酶/Akt信号通路刺激乳腺癌细胞的细胞运动性以及核因子κB介导的尿激酶型纤溶酶原激活剂(uPA)的分泌(达斯,R.,马哈贝莱什瓦尔,G. H.,以及昆杜,G. C.(2003年)《生物化学杂志》278,28593 - 28606)。然而,OPN在AP - 1介导的uPA分泌和细胞运动性方面的作用,以及c - Src/表皮生长因子受体(EGFR)在乳腺癌细胞这些过程中的参与情况尚未明确界定。在本研究中,我们报道OPN在高侵袭性(MDA - MB - 231)和低侵袭性(MCF - 7)乳腺癌细胞中均诱导α(v)β(3)整合素介导的c - Src激酶活性。OPN与α(v)β(3)整合素的结合在MDA - MB - 231和野生型EGFR转染的MCF - 7细胞中诱导EGFR的激酶活性和酪氨酸磷酸化,而这被c - Src的显性负性形式(dn c - Src)所抑制,表明c - Src激酶在此过程中起关键作用。OPN诱导α(v)β(3)整合素与细胞膜上的EGFR以与c - Src形成大分子形式相互关联。此外,OPN诱导α(v)β(3)整合素/EGFR介导的ERK1/2磷酸化和AP - 1激活。而且,dn c - Src也抑制了这些细胞中OPN诱导的磷脂酰肌醇(PI)3激酶活性,表明c - Src在调节MEK/ERK1/2和磷脂酰肌醇3激酶/Akt信号通路中起主导开关作用。当细胞用dn c - Src转染或用α(v)β(3)整合素抗体、c - Src激酶抑制剂(pp2)、EGFR酪氨酸激酶抑制剂(PD153035)和MEK - 1抑制剂(PD98059)预处理时,OPN诱导的ERK磷酸化、AP - 1激活、uPA分泌和细胞运动性均受到抑制。据我们所知,这是首次报道OPN通过激活c - Src/EGFR/ERK信号通路诱导α(v)β(3)整合素介导的AP - 1活性和uPA分泌,并进一步证明了OPN诱导的整合素/c - Src依赖性EGFR磷酸化与ERK/AP - 1介导的uPA分泌之间的功能性分子联系,而所有这些最终控制乳腺癌细胞的运动性。